Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

P2116

Sigma-Aldrich

Pirfenidone

≥97% (HPLC), powder, antifibrotic agent

Sinonimo/i:

5-Methyl-1-phenyl-2-(1H)-pyridone

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C12H11NO
Numero CAS:
53179-13-8
Peso molecolare:
185.22
Numero MDL:
MFCD00866047
Codice UNSPSC:
12352200
ID PubChem:
24278625
NACRES:
NA.77

product name

Pirfenidone, ≥97% (HPLC)

Saggio

≥97% (HPLC)

Forma fisica

powder

Solubilità

H2O: >10 mg/mL at 60 °C (warming for 30 minutes)
DMSO: >20 mg/mL

Ideatore

Shionogi

Stringa SMILE

O=C(C=CC(C)=C1)N1C2=CC=CC=C2

InChI

1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3
ISWRGOKTTBVCFA-UHFFFAOYSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

Pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone) is a synthetic derivative of pyridine.

Applicazioni

Pirfenidone has been used:
  • as a post-operative eye drop in rabbits to analyse its antifibrotic effect to improve glaucoma filtration surgery
  • as an anti-scarring agent to examine whether it affects the foreign body reaction after glaucoma drainage device (GDD) implantation in a rabbit
  • to test its antifibrotic potential in primary cultures of human orbital fibroblasts (hOFs)
  • as tumor necrosis factor (TNFα) inhibitor to study its effect in hypoxia

Azioni biochim/fisiol

Pirfenidone inhibits collagen production and fibroblast proliferation. It has shown antifibrotic and anti-inflammatory properties in variety of animal models of pulmonary fibrosis, and in clinical trials.
Pirfenidone is used to treat idiopathic pulmonary fibrosis (IPF). It helps to decrease the weakening of lung function decline and ameliorate progression-free survival. Pirfenidone can repress the multiplication and contraction of collagen of human tenon′s fibroblasts.

Caratteristiche e vantaggi

This compound was developed by Shionogi. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pittogrammi

Exclamation mark
GHS07

Avvertenze

Warning

Indicazioni di pericolo

H302

Classi di pericolo

Acute Tox. 4 Oral

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

dust mask type N95 (US), Eyeshields, Gloves

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 8

1 of 8

PF-3644022 hydrate ≥98% (HPLC)

Sigma-Aldrich

PZ0188

PF-3644022 hydrate

3-Hydroxy-2-methylpyridine 99%

Sigma-Aldrich

268534

3-Hydroxy-2-methylpyridine

Toremifene citrate salt ≥98% (HPLC)

Sigma-Aldrich

T7204

Toremifene citrate salt

5-Hydroxy-2-methylpyridine 99%

Sigma-Aldrich

107263

5-Hydroxy-2-methylpyridine

2-Amino-5-methylpyridine 99%

Sigma-Aldrich

A75684

2-Amino-5-methylpyridine

Relaxin-2 human recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture

Sigma-Aldrich

SRP3147

Relaxin-2 human

X-34 ≥90% (HPLC)

Sigma-Aldrich

SML1954

X-34

SIS3 ≥98% (HPLC), powder

Sigma-Aldrich

S0447

SIS3

CX3CL1 (fractalkine) and TNF alpha production by perfused human placental lobules under normoxic and hypoxic conditions in vitro: the importance of CX3CR1 signaling
Szukiewicz D, et al.
Inflammation Research, 63(3), 179-189 (2014)
Huzaifa I Adamali et al.
Drug design, development and therapy, 6, 261-272 (2012-10-12)
Over the past decade, there has been a cohesive effort from patients, physicians, clinical and basic scientists, and the pharmaceutical industry to find definitive treatments for idiopathic pulmonary fibrosis (IPF). As understanding of disease behavior and pathogenesis has improved, the
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
Lancaster L H, et al.
European Respiratory Review, 26(146), 170057-170057 (2017)
Arata Azuma
Therapeutic advances in respiratory disease, 6(2), 107-114 (2012-02-16)
Pirfenidone is the first antifibrotic agent to be approved for the treatment of pulmonary fibrosis. Idiopathic pulmonary fibrosis (IPF) is one of the idiopathic interstitial pneumonias with the worst prognoses; approximately half of patients die within 3-5 years, and the
K Huber et al.
Histochemistry and cell biology, 142(4), 361-371 (2014-05-16)
The aim of this study was to establish an ex vivo model for a faster optimisation of sample preparation procedures, for example matrix choice, in matrix-assisted laser desorption/ionisation (MALDI) drug imaging studies. The ionisation properties of four drugs, afatinib, erlotinib
Visualizza tutti i documenti correlati

Articoli

Bioactive Molecules for Immunology Research

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.